Literature DB >> 8380363

A robust strategy for screening and confirmation of familial defective apolipoprotein B-100.

C D Mamotte1, F M van Bockxmeer.   

Abstract

The diagnosis of familial defective apolipoprotein B-100 (FDB) has been facilitated by the use of mutagenic polymerase chain reaction (PCR) primers to introduce restriction sites at the FDB gene locus. We describe a two-test strategy for diagnosing FDB that overcomes the potential for error in single-test methods based on such techniques. We introduce an Sau96I restriction site for PCR products of the normal apolipoprotein B allele. Incomplete digestion of the PCR product with Sau96I suggests an FDB heterozygote, although a false-positive result due to nonideal digestion conditions remains a possibility. In such cases we use a second test that introduces an ScaI restriction site in PCR products of the FDB allele. The diagnosis is confirmed if half of this product can be digested with ScaI. Both tests use 0.25 units of Taq polymerase and are robust with respect to annealing temperature (31-58 degrees C) and to Mg2+ concentration (1.0-3.2 mmol/L).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380363

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Genotyping of single nucleotide substitutions.

Authors:  Cyril D S Mamotte
Journal:  Clin Biochem Rev       Date:  2006-02

2.  Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing.

Authors:  Steve E Humphries; Treena Cranston; Marcus Allen; Helen Middleton-Price; Maryam C Fernandez; Victoria Senior; Emma Hawe; Andrew Iversen; Richard Wray; Martin A Crook; Anthony S Wierzbicki
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

3.  Use of targeted exome sequencing as a diagnostic tool for Familial Hypercholesterolaemia.

Authors:  Marta Futema; Vincent Plagnol; Ros A Whittall; H Andrew W Neil; Steve Eric Humphries
Journal:  J Med Genet       Date:  2012-10       Impact factor: 6.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.